Possible reasons include the Washington State University patent holders not finding a pharmaceutical company willing to invest in development, the cancer biology concern with c-Met activation making development companies cautious, the preclinical effect sizes in rats not justifying the expense and risk of human trials, or other factors specific to drug development economics
What is a Vitamin Injection
Waluk DP, Sucharski F, Sipos L, Silberring J, Hunt MC (2012) Reversible lysine acetylation regulates activity of human glycine N -acyltransferase-like 2 (hGLYATL2): implications for production of glycine-conjugated signaling molecules
Recovery can take time, but taking a whole-person approach can help ensure no piece of the puzzle is overlooked
Jami Kinnucan, MD, and I examine both the ethical considerations and the strategic opportunities it presents for our field Worth a read for anyone navigating this space, whether you're advising on a trial, speaking on behalf of a therapy, or simply trying to make sense of where the lines should be drawn
